We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
reVision Therapeutics announced the US Food and Drug Administration (FDA) has granted the Company's request to designate REV-0100 as an Orphan-Drug and a Rare Pediatric Disease Drug for the treatment of Stargardt disease.
Belite Bio announced positive results from two Phase 1 clinical trials in the United States and Australia for LBS-008, a First-in-Class oral small molecule Retinol Binding Protein 4 (RBP4) specific antagonist aimed to treat atrophic Age-related ...